Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

NCT03485209 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms
Carcinoma, Non-Small-Cell Lung
Exocrine Pancreatic Cancer
Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG: tisotumab vedotin
DRUG: pembrolizumab
DRUG: carboplatin
DRUG: cisplatin

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Collaborators

[object Object]
[object Object]